The approval is relatively small: The drug, Elevidys, is indicated for 4- and 5-year-olds “with a confirmed mutation in the DMD gene who do not have a pre-existing medical reason preventing treatment with this therapy,” the FDA said.
Elevidys is a single intravenous dose that was granted accelerated approval after a clinical trial found the drug increased a protein present in normal muscle cells among patients aged 4 and 5. It will cost $3.2 million, its drugmaker Sarepta Therapeutics said June 22.
Most therapies for DMD focus on symptoms of the disease that affects about 1 in every 3,300 males and kills most patients in their 20s or 30s, but Sarepta’s newly approved medication is the first to target the condition’s genetic cause.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.